ClinicalTrials.gg
RecruitingNCT07065500HestiaUpdated Sep 2, 2025

Mechanism and Effect of Novel Metabolites on Valvular Heart Disease

An observational study in Valvular Heart Disease, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by Sun Yat-sen University · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Heart Valve Diseases with a site in China — 28 open to participants now, 30 under way, none of them phase 3. Heart Valve Diseases · China.

Planned enrollment
16th of 35
4,000 · median 3,000
Started
2025
with 2 others
Observational
35 of 69
17 open now
Primary completion
2030-03
later than 26 of 29 live
Registered
58th of 69
by date
Lead sponsor
4 of 69
Sun Yat-sen University

Among the 69 studies in Heart Valve Diseases with a site in China, this one is the 16th largest by planned enrollment of the 35 observational ones that give a count, is one of 3 that started in 2025, is one of 35 observational ones, reaches primary completion later than 26 of the 29 other live ones, and was the 58th registered.

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

28 of the 69 studies in Heart Valve Diseases with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Heart Valve Diseases with a site in China, or all of them as a file.
02

Study summary

Valvular heart disease (VHD) is a leading cause of loss of physical function, reduced quality of life and increased longevity.The epidemiology of VHD varies widely across the globe, with functional and degenerative diseases occurring predominantly in high-income countries and rheumatic heart disease occurring predominantly in low- and middle-income countries. The prevalence of valvular heart disease (VHD) is increasing globally due to improved survival and aging populations, poorly controlled by medications, with the majority of patients having to undergo surgical or interventional treatments.

It is therefore important to search for novel metabolites and conduct mechanistic studies on the effects of these metabolites on patients with heart valve disease.

In the Hestia study, the investigators looked for risk factors and mechanisms associated with the development and prognosis of VHD through long-term follow-up of VHD patients and metabolite testing of specimen tissues.

03

Conditions studied

  • Valvular Heart Disease

Browse trials for

Keywords

  • novel metabolites
  • valvular heart disease
  • prognosis
  • Risk Factors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients diagnosed with valvular heart disease during hospitalization were enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years, gender is not limited.
  2. Clinical diagnosis of heart valve disease (including aortic stenosis, aortic valve closure insufficiency due to different etiologies, mitral stenosis, mitral valve closure insufficiency, pulmonic stenosis, pulmonic valve closure insufficiency, tricuspid stenosis and tricuspid closure insufficiency due to different etiologies )

Exclusion criteria

Exclusion Criteria:

Patients unable to provide

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Clinical diagnosis of heart valve disease
06

What researchers measure

Primary outcomes

  1. Number of Participants with All-cause mortality

    Time frame: 5 years

Secondary outcomes

  1. Number of Participants with cardiovascular events

    Time frame: 5 years

  2. Number of Participants with progression of valvular heart disease

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2030, 55 months after the start.

Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 55 months is below that.

Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 15, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Mar 1, 2030
CompletionEst.
Mar 1, 2030
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07065500
Responsible party
Xiao-dong Zhuang (Principle Investigator, Sun Yat-sen University) — Principal investigator
First posted
Jul 15, 2025
Start date
Aug 1, 2025
Primary completion
Mar 1, 2030 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Sep 2, 2025

Study contacts

Xiaodong Zhuang
Contact
zhuangxd3@mail.sysu.edu.cn
+8613760755035

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion